Tickers: XTSX:VPT, PINX:VPTDF
Tags: #Technology, #Healthcare
Toronto, Ontario - TheNewswire - November 29, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTCQB:VPTDF) is exhibiting for the first time at the Radiological Society of North America's 105th Scientific Assembly and Annual Meeting (RSNA 2019), held in Chicago's McCormick Place from December 1-6. Join us at Booth #1133.
The conference is the world's largest radiology conference with 50,000 attendees, including professionals from 136 countries around the world who attend to see the latest technologies from the 700+ vendors in attendance, attend plenary and poster sessions, and for the 400+ educational courses.
This year's conference is particularly momentous for Ventripoint given that we recently received FDA clearance for our new model, VMS+ 3.0, and we aim to showcase the new system at this one-of-a kind conference. This will be a great opportunity to introduce the system to business leaders and healthcare professionals in radiology from around the world.
The VMS+ 3.0 connects to standard echocardiography machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology creating 3D images of the heart and calculates volumes & ejection fraction for all 4 cardiac chambers with accuracy equivalent to MRI. The system can reduce the need for MRI in pediatrics and adults.
"We are particularly excited about the changes we have made to the latest model of the device, including an interactive and intuitive navigational guide and the innovative tracking sensor technology that has considerably improved the user experience, and most importantly has built upon our legacy to improve patient's lives by providing innovative technology." - Justin Leushner, Ventripoint President & CEO.
About Ventripoint Diagnostics Ltd.
Ventripoint's VMS+ 3.0 connects to standard echo machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology to create 3D images of the heart and calculates volumes & ejection fractions with accuracy equivalent to MRI. The system provides consistent, reproducible results for all four chambers of the heart including the difficult to measure RV for adult and pediatric patients.
For further information please contact:
Justin Leushner, CEO
Telephone: (416) 848-4156
Email: jleushner@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Copyright (c) 2019 TheNewswire - All rights reserved.
